Key Takeaway:
- Tzield FDA Approval for children aged one and older with stage 2 type 1 diabetes.
- Therapy can delay progression to insulin dependence by about two years.
- Early screening becomes critical to identify eligible children before symptoms appear.
The U.S. Food and Drug Administration approved Tzield for children aged one and older with stage 2 type 1 diabetes, allowing early treatment that can delay disease progression and postpone insulin dependence by an average of two years.
FDA Approval Opens Early Treatment Path for Young Children
The U.S. Food and Drug Administration on Thursday approved Tzield (teplizumab-mzwv) for children aged one and older diagnosed with stage 2 type 1 diabetes, expanding access to the first disease-modifying therapy targeting the autoimmune cause of the condition.
The decision marks a major shift in diabetes treatment by addressing the underlying immune attack rather than managing symptoms after insulin dependence begins.
Health experts say the therapy offers families time before the disease progresses to stage 3 type 1 diabetes, when lifelong insulin therapy becomes necessary. Patients receive a single 14-day infusion course designed to slow immune system damage to insulin-producing beta cells.
Aaron Kowalski, CEO of Breakthrough T1D, called the approval a turning point.
“Tzield FDA Approval for use in children ages one and older marks a defining moment in the treatment of type 1 diabetes,” Kowalski said. “Intervening earlier and slowing the disease’s progression will provide the gift of time to young children and their caregivers.”
Years of Research Lead to Expanded Access
Following initial Tzield FDA approval in 2022 for patients aged eight and older with stage 2 type 1 diabetes. Researchers, advocacy groups, and drug manufacturer Sanofi have since worked to broaden eligibility to younger patients and additional disease stages.
Breakthrough T1D funded decades of research contributing to the therapy’s development, beginning with early studies in the late 1980s demonstrating that anti-CD3 antibodies could interrupt autoimmune diabetes.
Clinical trials supported by the organization, the National Institutes of Health, and international research networks later confirmed that Tzield could delay the onset of clinical diabetes in individuals almost certain to develop the disease.
“This approval reflects years of collaboration among researchers, regulators, and patient advocates,” Kowalski said, adding that expanding access allows more families to benefit from earlier intervention.
Sanofi officials said the company remains committed to advancing therapies that modify disease progression rather than relying solely on insulin management.
Screening Gains Urgency as Treatment Options Grow
Advocates say the expanded approval increases the importance of early screening for type 1 diabetes, even among children without a known family history.
Stage 2 diabetes often develops without symptoms, meaning screening is currently the only way to identify eligible patients before insulin therapy becomes necessary.
Breakthrough T1D highlighted the experience of community member Chris Dunn, a parent of four children, two living with type 1 diabetes. After participating in screening because of family risk, Dunn discovered she was in stage 2 disease and chose Tzield treatment to delay insulin dependence.
Medical groups say early detection combined with treatment could spare families years of daily glucose monitoring, insulin injections, and dangerous blood sugar fluctuations.
Researchers continue to evaluate Tzield for individuals already in stage 3 type 1 diabetes, following encouraging results from the PROTECT clinical study, which showed a slowed decline in beta cell function.
Advocacy organizations and researchers say the long-term goal is a future where multiple disease-modifying therapies preserve insulin production and transform type 1 diabetes from a lifelong burden into a manageable, delayed condition.
